logo
Share SHARE
FONT-SIZE Plus   Neg

Palatin Says Partner AstraZeneca To Stop Further AZD2820 Drug Development

Palatin Technologies, Inc. (PTN), a New Jersey-based Pharma company, Friday said its partner AstraZeneca will stop all further development of the obesity drug AZD2820.

AZD2820, a clinical candidate under development by AstraZeneca with Palatin, was halted following a serious adverse event in its Phase I trial, subsequently followed by AstraZeneca' decision to discontinue its development.

In addition, Palatin said it was eligible for milestone payments, subject to certain development and regulatory milestones with further payments on achievement of sales targets.

Thursday, Palatin closed at $0.64 on the NYSE market.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The bench to bedside journey of drugs is fraught with challenges. It is estimated that only 5 in 5,000 compounds that enter preclinical testing make it to human testing, and out of those 5, only 1 may pass through all the regulatory hurdles needed to reach pharmacy shelves. Major League Baseball is talking expansion for the first time in a few decades. Owners stand to make a pretty penny from expansion fees and subsequent television rights. The possibility of a more balanced schedule is also enticing. Strong expansion candidates in the U.S. and Canada are ready... The New York Times is teaming up with Google again to give away Google Cardboard, the virtual reality headsets, but this time only to its "most loyal" digital subscribers. The company said that the digital-only subscribers selected for this distribution were chosen based on the duration of their subscriptions.
comments powered by Disqus
Follow RTT